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ABSTRACT
Midodrine prevents post-space flight orthostatic intolerance when testing is conducted in
a controlled laboratory setting within 2-4 hours after Space Shuttle landing. It is
unknown if midodrine is as effective during re-entry and immediately following landing.
METHODS: Cardiovascular responses to 10 minutes of 80° head-up tilt in five male
astronauts were compared before and immediately after Space Shuttle missions. Pre-
flight tests were conducted in the Johnson Space Center Cardiovascular Laboratory
without midodrine. Post-flight testing was performed in the Crew Transport Vehicle on
the Space Shuttle runway within 60 minutes of landing; midodrine was self-administered
before re-entry. Survival analysis was performed (Gehan-Breslow test) to compare
presyncope rates pre- to post-flight. Cardiovascular responses (last minute standing
minus supine) to tilt before and after space flight were compared using paired t-tests.
RESULTS: Midodrine did not prevent post-flight orthostatic hypotension in two of the
five astronauts, but the rate of presyncope across the group did not increase (p=0.17)
from pre- to post-flight. Also, although the change in heart rate from supine to the last
minute of standing was not affected by space flight, systolic blood pressure decreased
more (p=0.05) and diastolic blood pressure tended to decrease (p=0.08) after space flight.
CONCLUSIONS: Accurate interpretation of the current results requires that similar data
be collected in control subjects (without midodrine) on the CTV. However, drug
interaction concerns with commonly used anti-emetics and potentiation of prolonged QTc
intervals observed in long duration astronauts make the routine use of midodrine for
immediate post-flight orthostatic hypotension unlikely.
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INTRODUCTION
Following space flight, the capability to remain upright (standing) may be compromised
by an inability to maintain adequate arterial pressure and cerebral perfusion. This
condition, termed orthostatic or postural hypotension, may result in presyncope
(lightheadedness) or syncope (loss of consciousness) during re-entry or egress from the
space vehicle and for several days after landing. A significant number of astronauts
experience post-flight orthostatic hypotension, and its severity and incidence increases as
the length of microgravity exposure is extended. Approximately 20% of short-duration
and 80% of long-duration crewmembers experience presyncope during testing on landing
day (15). We expect that orthostatic hypotension also will be a significant concern
following exploration class space flight missions when medical assistance will be limited
or even unavailable. The development of an effective countermeasure may be critical to
the success of these missions, and post-flight orthostatic hypotension is listed as a high
priority in the HHC Integrated Research Plan (Gap CV3).
To date, the potential countermeasures that have been tested (e.g., lower body negative
pressure, fluid loading, Florinef, exercise) have not eliminated post-flight orthostatic
hypotension. Midodrine is a selective alpha-1 adrenergic agonist which is used clinically
to treat orthostatic hypotension. It is almost completely absorbed after oral
administration and is hydrolyzed enzymatically to its active metabolite, desglymidodrine,
which has a bioavailability of 93% (11; 13);(14). Midodrine acts by increasing
vasoconstriction and decreases peripheral venous capacity, prevents blood pooling, and
increases total peripheral resistance (14), but does not pass the blood-brain barrier and
therefore has no central stimulant effects (13). The effects of midodrine may be
particularly protective of orthostatic tolerance in astronauts who become presyncopal on
landing day due to inadequate release of norepinephrine (9).
Midodrine as a countermeasure to orthostatic intolerance was evaluated in two phases.
In Phase I, 10 mg of midodrine was given orally to astronauts two hours after the landing
of a Space Shuttle mission and one hour prior to an 80 ˚ head-up tilt test administered in
NASA’s data collection facility at the landing site. In five male astronauts, heart rate
during upright tilt was not significantly elevated compared to preflight with midodrine
administration. Other hemodynamic responses to tilt were not different than pre-flight,
and no crewmember experienced hypertension after consuming this adrenergic agonist.
Importantly, heart rate was significantly greater in these crewmembers following a
previous mission of similar duration when they had not taken the drug (17). Additionally,
orthostatic intolerance was prevented in one female crewmember during tilt after taking
midodrine following a Space Shuttle mission even though she had become presyncopal
during a stand test of similar duration following a previous Space Shuttle flight (18).
In Phase II, midodrine was administered to crewmembers in the manner in which it might
be used routinely following space flight. Midodrine was administered to five male
astronauts one hour before landing, near the time of firing the Shuttle main engines to
decelerate the Orbiter and begin its descent. The peak therapeutic effect of midodrine
occurs approximately one hour after ingestion (18);(10);(25), making it particularly
attractive as landing day countermeasure, such that its peak effect is close to the time of
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the maximum gravitational forces during landing (17). The purpose of this report is to
summarize the preliminary findings from Phase II of this countermeasure evaluation.
The strength of this study is that crewmembers participated in the post-flight tilt test of
orthostatic tolerance within 30 minutes after wheelstop such that their physical status
more closely represented their condition during re-entry and immediately upon landing.
METHODS
Overall Protocol
Eight crewmembers volunteered to participate in this countermeasure evaluation. Three
subjects withdrew from participation following the collection of pre-flight data. Two
subjects were waived from participation: one demonstrated a prolonged QTc interval on
an electrocardiogram during in-flight screening and one experienced significant
neurovestibular disturbances on landing day. One crewmember voluntarily withdrew
from participation following the pre-flight midodrine tolerance test.
In the course of this study, countermeasure subjects participated in a familiarization
session and drug tolerance test, an 80 ˚ head-up tilt test without medications
approximately 10 days before launch (L-10), and the tilt test protocol within 60 minutes
of Shuttle landing (R+0). Protocols were reviewed and approved by the Committee for
the Protection of Human Subjects at NASA-Johnson Space Center (JSC). Subjects
received verbal and written explanation of all procedures and signed statements of
informed consent prior to participation.
Preflight Activities
Approximately 90 days before the scheduled launch date, subjects were briefed on test
protocols and procedures. Afterwards, crewmembers participated in a midodrine
tolerance test. A 12-lead electrocardiogram was first obtained to insure that the
crewmember’s QTc interval was within acceptable limits for ingestion of midodrine
(<0.45 sec for men, <0.47 sec for women). Once verified, the crewmember’s baseline
systolic (SBP) and diastolic blood pressure (DBP) was measured. Following the
ingestion of 10 mg midodrine, blood pressure was monitored at regular intervals during
normal activities for four hours by trained personnel using a manual sphygmomanometer.
Crewmembers were requested to report any unusual experiences or symptoms during this
four-hour monitoring period and completed an activity log.
Approximately 10 days before launch (L-10), crewmembers participated in a tilt test in
the JSC Cardiovascular Laboratory. Six minutes of supine data were collected prior to
tilting the subjects to 80° head-up tilt using an automatic tilt table. The subjects remained
in this position for 10 minutes, or until symptoms of orthostatic hypotension (SBP<70
mmHg, sudden drop in heart rate>15 beats·min -1 , sudden drop in SBP> 25 mmHg,
sudden drop in DBP>15 mmHg, bradyarrythmia) and/or presyncope occurred (severe
nausea, clammy skin, perfuse sweating, pallor, light-headedness, dizziness, or tingling).
Subjects were discouraged from movement, muscle contractions, talking (except to report
symptoms), and were encouraged to breathe normally. Subjects were returned to the
supine posture upon termination of the test protocol.
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Subjects were instrumented to measure ECG (Escort II, MDE, Arleta, CA) for heart rate
(HR) and rhythm, beat-to-beat blood pressure in the finger (Finapres 2300 blood pressure
monitor, Ohmeda, Englewood, CO), and blood pressure each minute in the brachial
artery (Dinamap XL Vital Signs Monitor, GE Medical Systems Information
Technologies, Milwaukee, WI). Two-dimensional echocardiography was used to obtain
the aortic annulus diameter from the parasternal long axis during supine rest prior to data
collection. Ascending aortic blood velocity time integral was measured each beat during
rest and tilt from pulse wave Doppler measurements made at the suprasternal notch using
a 2 MHz probe (Biosound MyLab 30, Esoate, Indianapolis, IN) (3). Images were
digitally stored for offline analysis. Images from three cardiac cycles collected at a time
corresponding to the heart rate and blood pressure data were independently analyzed by
two experienced sonographers. Sonographers were blinded to the test conditions during
the analyses. Stroke volume (SV=annulus diameter x velocity time integral), cardiac
output (CO=stroke volume x heart rate) and total peripheral resistance (TPR=mean
arterial pressure/cardiac output) were calculated.
In Flight Activities
Crewmembers participated in their scheduled in-flight activities without restriction for
the duration of their Shuttle mission. After the decision for deorbit burn was confirmed
on the scheduled landing day, crewmembers donned the Advanced Crew Escape Suit
(ACES) and ingested 10 mg of midodrine approximately one hour prior to the scheduled
landing time. The midodrine pill and a cue card with medication instructions were
stowed previously in the astronaut’s ACES for their convenience. Crewmembers
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participated in the standard oral fluid loading protocol (equivalent to isotonic saline at a
rate of 15 ml·kg-1 within two hours of landing (18)) and inflated their antigravity suits
during re-entry and landing.
Post -flight Activities
Post-flight testing on landing day (R+0) was conducted on the Shuttle runway at either
Kennedy Space Center, FL, or Dryden Flight Research Center, CA, in NASA’s Crew
Transport Vehicle (CTV), a modified airport “people mover” used to transport the
crewmembers from the Space Shuttle to the data collection facility. After Shuttle wheel
stop, the CTV approached the Orbiter with the rest of the NASA convoy, and the Shuttle
hatch was opened within ~20 min. After a brief medical check by the NASA Flight
Surgeons, the crewmembers exited the Orbiter with the midodrine test subjects exiting
first. The crewmember doffed their ACES within 5 min and participated in the same tilt
test protocol as during the pre-flight assessment.
Statistical Analyses
Hemodynamic and heart rate data were collected during the tilt test. The last minute of
supine data was used as baseline. Standing values represent the data at the end of the tilt
test: either after 10 minutes of tilt or when symptoms of orthostatic hypotension
(presyncope) intervened.
Survival analysis was performed using the Gehan-Breslow test to compare the rate of
presyncope during tilt at L-10 in the JSC Cardiovascular Laboratory and during tilt on
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R+0 when testing was performed on the CTV. Because of the small number of subjects
in this study, inferential statistics should be viewed with caution. Paired t-tests were
conducted to determine whether there was a significant change in the heart rate and
hemodynamic variables from supine to the last minute of tilt within each day. Then,
paired t-tests were performed to compare the heart rate and hemodynamic responses (last
minute standing minus supine) to tilt before and after space flight. Heart rate and blood
pressure data were available for all five subjects on L-10 and R+0. However, SV, CO,
and TPR data were not available for two subjects on R+0. Therefore, no inferential
statistics were performed with these data.
Mean differences were considered significant if p < 0.05. Statistical analysis was
performed using the software package SigmaPlot for Windows, version 11.0 (Systat
Software, Inc.). Data are presented as means ± SEM.
RESULTS
On L-10, all five subjects completed the full 10 minutes of 80° head-up tilt in the
laboratory without developing signs or symptoms of presyncope. When testing was
performed in the CTV on R+0, only three of the five crewmembers completed the full 10
minutes of tilt. In this small group of subjects, the rate at which pre-syncope developed
was not different (p=0.17) between testing in the laboratory on L-10 and testing on the
CTV on R+0 (FIGURE 1).
INSERT FIGURE 1 HERE
HR increased from supine to tilt (TABLE I) both on L-10 (20±2 beats •min-1 , p<0.001)
and on R+0 (25±9 b eats •min-1 , p=0.05), but the change in HR from supine to tilt was not
different from L-10 to R+0 (p=0.55, FIGURE 2). In contrast, SBP did not significantly
change from supine to tilt either on L-10 (+3±5 mmHg, p=0.62) or on R+0 (-27±15
mmHg, p=0.15); however, the change in SBP from supine to tilt was different from L-10
to R+0 (p=0.05). DBP increased from supine to tilt on L-10 (+7±2 mmHg, p=0.03), but
DBP did not change from supine to tilt on R+0 (-12±8 mmHg, p=0.21). Similar to SBP,
the change in DBP from supine to tilt tended to be different on R+0 than L-10 than on L-
10 (p=0.08).
Supine and tilt echocardiographic data were not statistically tested but are displayed in
Table I.
INSERT TABLE I HERE
INSERT FGURE 2 HERE
DISCUSSION
This study represents the conclusion of Phase II of testing of midodrine as a
pharmacological countermeasure to post-space flight orthostatic intolerance. The unique
aspects of this investigation were that (a) this was the first time that a medication had
been administered immediately prior to Space Shuttle re-entry and landing to protect
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against orthostatic intolerance and (b) this was the first time that tilt tests were conducted
on the CTV as an opportunity to examine orthostatic responses immediately after
landing. In these five crewmembers, the rate of presyncope was not increased from pre-
flight without midodrine to post-flight with midodrine. However, although the HR
response to tilt was not changed from pre- to post-flight, midodrine did not prevent a drop
in a blood pressure after space flight. Unfortunately, because of the unique operational
aspects of this study, there were no control data (without midodrine) collected on the
CTV to which comparisons could be made and conclusions drawn.
Post-flight orthostatic hypotension is one of the consequences of cardiovascular
adaptations to microgravity that negatively impacts crew safety (1);(2);(6);(7);(9). Some
crewmembers are so affected that they require assistance when exiting the Shuttle.
Susceptibility to orthostatic hypotension is individual, with some astronauts experiencing
severe symptoms, while others are less affected (8). Presyncopal astronauts, who exhibit
severe orthostatic hypotension, have significantly lower standing plasma norepinephrine
levels and total peripheral resistance than their crew mates who do not become
presyncopal (9). These symptoms resemble those seen in patients with orthostatic
hypotension due to autonomic dysfunction (9);(13).
Midodrine has proven to be a very safe and effective therapy for orthostatic hypotension
due to autonomic dysfunction (5); (11);(13);(14);(20);(22);(24). In a randomized,
double-blind, multicenter study with 171 patients with neurogenic orthostatic
hypotension, Midodrine (10 mg dose, 3 times per day) resulted in substantial increases in
11
standing systolic blood pressure (increase of 22 mm Hg) with corresponding reductions
in subjective symptoms such as lightheadedness over patients given placebo (13). In a
second study, midodrine improved the following orthostatic hypotension symptoms:
dizziness/lightheadedness, weakness/fatigue, syncope, low energy level, impaired ability
to stand, and feelings of depression (11). The usual dose of midodrine is 5-10 mg orally
three times a day (22);(24). When given to healthy subjects, midodrine only modestly
increases supine and standing arterial pressure (increases less than 10 mm Hg) and
decreases heart rate (less than 10 bpm) (5);(14).
The National Space Biomedical Research Institute’s Cardiovascular Alterations Team
conducted a two-week head-down bed-rest study (an analogue of space-flight) in normal
human volunteers to simulate the effects of weightlessness on the cardiovascular system
(19). They tested midodrine as a countermeasure for the post-bedrest orthostatic
hypotension commonly observed during tilt testing. Five mg of midodrine significantly
increased blood pressure and reduced fainting during post-bed rest tilt tests. The
investigators concluded that midodrine might be an effective countermeasure for the
prevention of orthostatic intolerance in astronauts following spaceflight.
For these reasons, we evaluated midodrine as a countermeasure to orthostatic intolerance
after space flight. Because there were concerns about the safety of performing these
studies in astronauts during re-entry and landing, the implementation took place in two
phases. In Phase I, midodrine was administered to crewmembers after space flight, and
testing was conducted in the controlled environment of the laboratory at the landing sites.
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The primary finding of this experiment was that orthostatic responses in five male
crewmembers after a Space Shuttle mission were not different than that which they
experienced pre-flight. Additionally, their post-flight HR response with midodrine was
less than the post-flight HR response following a previous Space Shuttle mission, and
midodrine did not cause hypertension (17). Further, the administration of midodrine
appeared to have prevented orthostatic intolerance after an 11-day mission in one female
astronaut who had become presyncopal during a tilt test administered following a
previous flight of nine days (18).
However, the second phase of this study examined the efficacy of midodrine immediately
upon landing, in a less controlled and more provocative environment, onboard the CTV.
This type of operationally-relevant environment was necessary to determine the true
efficacy of midodrine as a countermeasure to immediate post-spaceflight orthostatic
hypotension. The actual effectiveness of midodrine in this environment is unknown; it is
not known how a crewmember would react to an orthostatic challenge immediately after
landing without a countermeasure. Temperatures onboard the CTV were above 80°F in
some cases, and the rocking of the vehicle further confounded the results of the tilt test.
For example, elevated body temperature, secondary to increased ambient temperature
(21) and impaired thermoregulation after space flight (4);(12), will result in decreased
orthostatic tolerance (23). The most similar control group, astronauts tested in the
baseline data collection facility after spaceflight, has two to four hours of upright
ambulation in which to re-acclimate to Earth’s gravity environment. Furthermore, these
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crewmembers have the opportunity to eat and consume additional fluids before testing in
a laboratory setting.
Hazards of Use of Midodrine
There is no central nervous system or cardiac stimulation with midodrine. The most
frequent side-effect is pilomotor reactions (skin crawling sensation) in <8% of patients.
Other less frequently reported side-effects are nausea, heartburn, dizziness, restlessness,
and reflex bradycardia. Some reflex bradycardia may occur when BP is increased. Risk
mitigation steps involve a drug tolerance test for each individual before its use during
space flight, which we conducted for this experiment. Possible drug interactions also
include the following: alpha- or beta-adrenergic agonists or blocking agents, especially
digitalis glycosides; sodium-retaining corticosteroids; or vasoconstricting medications.
Subjects were instructed not to take any of these drugs with midodrine before (drug
tolerance test) and after space flight (landing day).
In addition, a drug interaction may exist with promethazine. There is the potential that
midodrine and promethazine will interact when given together. In subjects that have
received both of these medicines, in a previous study performed by our laboratory, we
noted changes in mood and increased restlessness (16). The subjects described feelings of
“anxiety”, “aggressiveness”, “claustrophobia”, and a “need to constantly shift about”.
These changes in mood and restlessness were noticed about 10 minutes after subjects
received an intravenous dose of promethazine and had been given midodrine one hour
prior. Symptoms resolved within 30 to 45 minutes, and no lasting effects in mood or
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restlessness were reported or observed in these subjects. If midodrine were to be
eventually used as part of the preventive care in subjects known to have a propensity
towards orthostatic hypotension, it could not be administered in those crewmembers in
whom promethazine was administered before landing, while in the CTV or at the baseline
data collection facility. Based upon our previous experiences in the laboratory, we
recommend that no promethazine may be administered within 70 hours prior to
midodrine ingestion or within 4 hours following midodrine ingestion.
Summary
Midodrine appears to prevent orthostatic intolerance in test subjects after bed rest and in
astronauts following space flight when testing is conducted in a controlled, laboratory
setting within 2-4 hours after landing. It is unclear at this time whether similar effects
can expected during re-entry and immediately following landing, particularly in warmer
environments and/or when the crewmembers are still wearing the ACES. Accurate
interpretation of the current data require similar data be collected in control subjects
(without midodrine) on the CTV. However, concerns with drug interactions with
commonly used commonly used anti-emetics and prolonged QTc intervals observed in
long duration astronauts make the routine use of midodrine unlikely and reliance upon
lower body compression garments preferential.
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FIGURE LEGENDS
FIGURE 1. The probability of completing a 10-minute 80° head-up tilt test in the
laboratory before space flight (L-10, solid line) was not different (p=0.17) than the
probability of completing a tilt test on landing day (R+0, dashed line) in the Crew
Transport Vehicle in five astronauts.
FIGURE 2. Change in heart rate (HR), systolic blood pressure (SBP), diastolic blood
pressure (DBP), stroke volume (SV), cardiac output (CO), and total peripheral resistance
(TPR) from last minute of supine rest to the last minute of tilt in the laboratory before
flight (L-10) and on landing day (R+0) in the Crew Transport Vehicle. *Significantly
different than L-10 (p<0.05).
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Table I. Hemodynamic variables during the last minute of supine rest and at tilt test
termination. *Significantly different than supine.
L-10
	
R+0
Supine Tilt Supine Tilt
Heart Rate (beats •min-1 , n=5) 54±3 74±3* 58±2 82±8*
Systolic Pressure (mmHg, n=5) 121±6 124±7 131±2 104±15
Diastolic Pressure (mmHg, n=5) 67±4 74±4* 76±2 64±8
Stroke Volume (ml, n=3) 69±6 29±4 73±7 29±6
Cardiac Output (L •min-1 , n=3) 3.8±0.6 2.3±0.4 4.3±0.5 2.4±0.1
Total Peripheral Resistance
24.9±3.6 42.9±6.1 22.5±2.8 28.5±5.7
(mmHg• L-1•min-1 , n=3)
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